A blood test to detect which people with failing memories will go on to develop Alzheimer’s disease has been developed by British scientists, who hope it may prove a breakthrough in the hunt for a cure.
After a decade’s work, an international collaboration led by scientists from King’s College London, with the UK company Proteome Sciences, has published a study identifying a set of 10 proteins in the blood. The test can predict the onset of Alzheimer’s in the next 12 months in people with memory problems with an accuracy of 87 percent. It could cost £100 to £300 and be available within two years.
Alzheimer’s and other forms of dementia are distressing and a huge burden on those affected, their families and health services. However, despite the growing problem as people live longer, there are no good long-term treatments and there is no cure. British Prime Minister David Cameron recently announced a drive to discover new drugs for dementia, which he said “stands alongside cancer as one of the greatest enemies of humanity.”
As one potential drug after another has fallen by the wayside, scientists have begun to look for ways to treat people at a much earlier stage, when their brain is not so badly damaged. However, to do that, they need a test to predict who is going to develop the disease.
Scientists in the US published details in March of a proposed test for lipids (fatty chemicals) in the blood of people in the general population who do not have memory problems. However, such a screening test would be controversial: Few healthy people want to know they may be in line for an incurable disease that can be neither prevented nor treated.
The new test is aimed at people with the kind of memory loss called mild cognitive impairment, 60 percent of whom will go on to develop dementia. Those are the people scientists now want to recruit into trials to prevent, or at least delay, the onset of Alzheimer’s.
“Alzheimer’s begins to affect the brain many years before patients are diagnosed with the disease,” King’s College professor Simon Lovestone said. “Many of our drug trials fail because by the time patients are given the drugs, the brain has already been too severely affected.”
“A simple blood test could help us identify patients at a much earlier stage to take part in new trials and hopefully develop treatments which could prevent the progression of the disease,” he added.
The researchers investigated 26 proteins which have all been linked to Alzheimer’s in the past. Writing in the journal Alzheimer’s & Dementia, they say they took blood samples from 1,148 individuals, of whom 476 had Alzheimer’s disease, 220 had mild cognitive impairment and 452 were elderly, but without dementia.
They found that 16 of the proteins were associated with brain shrinkage either in mild cognitive impairment or Alzheimer’s.
In a second set of tests, they identified 10 proteins whose presence could predict, with a reasonable degree of accuracy, whether people with mild cognitive impairment would develop Alzheimer’s within a year.
Larger trials involving 5,000 to 10,000 people are still needed, the scientists say.
“The next step will be to validate our findings in further sample sets, to see if we can improve accuracy and reduce the risk of misdiagnosis, and to develop a reliable test suitable to be used by doctors,” Lovestone said.
Other scientists were enthusiastic about the potential for the test to aid drug discovery, but cautious about its potential use for diagnosing the disease in otherwise healthy people.
Eric Karran, science director at the charity Alzheimer’s Research UK, which helped fund the research, said a test identifying those at risk of Alzheimer’s at an early stage would be of “real value,” but warned that it would have to be used responsibly.
“Alzheimer’s disease is now the most feared diagnosis,” he said. “We have to be very careful about how we use these tests, especially in the absence of effective therapy.”
“Finding a way to detect dementia before symptoms develop would revolutionize research into the condition... However, this research does not mean that a blood test for dementia is just around the corner,” Alzheimer’s Society head of research James Pickett said.
“These 10 proteins can predict conversion to dementia with less than 90 percent accuracy, meaning one in 10 people would get an incorrect result. Therefore, accuracy would need to be improved before it could be a useful diagnostic test,” he added.
Far from the violence ravaging Haiti, a market on the border with the Dominican Republic has maintained a welcome degree of normal everyday life. At the Dajabon border gate, a wave of Haitians press forward, eager to shop at the twice-weekly market about 200km from Haiti’s capital, Port-au-Prince. They are drawn by the market’s offerings — food, clothing, toys and even used appliances — items not always readily available in Haiti. However, with gang violence bad and growing ever worse in Haiti, the Dominican government has reinforced the usual military presence at the border and placed soldiers on alert. While the market continues to
An image of a dancer balancing on the words “China Before Communism” looms over Parisian commuters catching the morning metro, signaling the annual return of Shen Yun, a controversial spectacle of traditional Chinese dance mixed with vehement criticism of Beijing and conservative rhetoric. The Shen Yun Performing Arts company has slipped the beliefs of a spiritual movement called Falun Gong in between its technicolored visuals and leaping dancers since 2006, with advertising for the show so ubiquitous that it has become an Internet meme. Founded in 1992, Falun Gong claims nearly 100 million followers and has been subject to “persistent persecution” in
ONLINE VITRIOL: While Mo Yan faces a lawsuit, bottled water company Nongfu Spring and Tsinghua University are being attacked amid a rise in nationalist fervor At first glance, a Nobel prize winning author, a bottle of green tea and Beijing’s Tsinghua University have little in common, but in recent weeks they have been dubbed by China’s nationalist netizens as the “three new evils” in the fight to defend the country’s valor in cyberspace. Last month, a patriotic blogger called Wu Wanzheng filed a lawsuit against China’s only Nobel prize-winning author, Mo Yan (莫言), accusing him of discrediting the Communist army and glorifying Japanese soldiers in his fictional works set during the Japanese invasion of China. Wu, who posts online under the pseudonym “Truth-Telling Mao Xinghuo,” is seeking
‘SURPRISES’: The militants claim to have successfully tested a missile capable of reaching Mach 8 and vowed to strike ships heading toward the Cape of Good Hope Yemen’s Houthi rebels claim to have a new, hypersonic missile in their arsenal, Russia’s state media reported on Thursday, potentially raising the stakes in their attacks on shipping in the Red Sea and surrounding waterways against the backdrop of Israel’s war with Hamas in the Gaza Strip. The report by the state-run RIA Novosti news agency cited an unidentified official, but provided no evidence for the claim. It comes as Moscow maintains an aggressively counter-Western foreign policy amid its grinding war on Ukraine. However, the Houthis have for weeks hinted about “surprises” they plan for the battles at sea to counter the